This organization files Form 990, which has no section for application policy. Its filings cannot say either way.
The latest filing we hold carries no statement about applications. That is not the same as closed: public-charity Form 990s have no field for it, and many foundations leave the section blank.
Grants paid by year
Total assets by year
Where the money went · FY2025
Form 990 splits expenses into program services, management and fundraising. The split is self-reported, and a grantmaker, a research institute and a direct-service nonprofit book the same work differently. A line the return does not carry reads "not available"; it is never counted as zero.
| Year | Form | Revenue | Expenses | Grants paid | Assets | Net assets |
|---|---|---|---|---|---|---|
| FY2025 | 990 | $1,259,978 | $1,435,203 | $262,500 | $1,489,567 | $1,410,220 |
| FY2024 | 990 | $1,229,594 | $1,251,534 | $187,500 | $1,660,128 | $1,585,445 |
| FY2023 | 990 | $1,477,220 | $1,127,598 | $80,000 | $1,720,466 | $1,607,385 |
| FY2022 | 990 | $1,285,088 | $1,149,439 | $195,000 | $1,317,945 | $1,257,763 |
| FY2021amended | 990 | $1,194,306 | $932,955 | $150,000 | $1,150,164 | $1,122,114 |
| FY2020 | 990 | $942,152 | $653,816 | $75,000 | $887,172 | $860,763 |
Figures are as reported on the e-filed return, with no restatement. Fiscal years are the funder's own tax year, labelled by the calendar year the period ends in. A blank line means the return does not carry that figure; a real zero shows as $0. When an amended return replaces an original, every figure here uses the amended return. The original is not shown. Giving is what the funder actually paid out toward its charitable purpose in the year (qualifying distributions on Form 990-PF, charitable disbursements otherwise). Assets are what it holds; giving is what moves.
Recipient focus areas
Where recipients are
Based on the 63% of grant rows we could match to an organization record. The rest stay as reported. The IRS assigns the NTEE category when it grants exemption. It often reflects the original filing, not today's giving.
| Recipient | Purpose | Amount | Year | Source |
|---|---|---|---|---|
| Emory UniversityAtlanta, GA | 2024 Julie Swedberg YOLO Award | $75,000 | 2025 | |
Recipients are shown as the funder wrote them on the return. A recipient with a link was matched to an organization record; the rest stay as reported and are never guessed.
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| Justin Ballsrud | Board member | 0.50 | $0 |
| Peter Bucka | Board member | 0.50 | $0 |
| Jonathan Hovda | Board member | 0.50 | $0 |
| Teri Kast | Board member |
From the officer list on the latest e-filed return. Compensation is as reported there; a blank means the return carries no figure.
| 2023 Peg's Fight for Life Award |
| $75,000 |
| 2025 |
| Mayo ClinicRochester, MN | 2023 Peg's Fight for Life Award | $75,000 | 2024 |
| University of Texas SouthwesternDallas, TX | The research project is seeking to understand the role of Telmerase that is expressed by most human cancers, particularly small cell lung cancer. We will target an essential survival mechanism of tumor cells to activate protective antitumor immunity and immune memory. We hypothesize that sytosolic DNA resulting from targeting telmerase with 6TdG treatment induces the cGAS/STING pathway, leading to enhanced antigen presentation and cyokine expression from tumors and dendritic cells (DC), causing the expansion and activation of tumor-specific T cells. If successful, our studies will guide the design of clinical trials. Given that NIH considers SCLC a recalcitrant disease, we believe SCLCs can easily be prioritized to be one of the first cancers to test 6TdG as these tumors do not have effective treatments currently. If we can generate strong preclinical evidence with this proposal, 6TdG can rapidly move in this subset in the clinic. | $75,000 | 2021 |
| Albert Einstein College of MedicineBronx, NY | 2024 Peg's Fight for Life Award | $75,000 | 2025 |
| Whitehead Institute of Biomedical ResearchCambridge, MA | This research project focuses on improving lung cancer outcomes with two aims: 1) To determine the mechanism by which macrophage activation enhances the response to EGFR TKIs; and 2: To investigate the anti-tumor efficacy of EGFR TKIs in combination with macrophage-directed therapies in xenograft models. | $75,000 | 2021 |
| Massachusetts General HospitalBoston, MA | Pegs Fight for Life Award | $75,000 | 2023 |
| Whitehead Inst for BiomedicalCambridge, MA | Peg Fisher 2021 Research Award | $75,000 | 2022 |
| Massachusetts GeneralBoston, MA | Pegs Fight for Life Award | $37,500 | 2022 |
| Albert Einstein College of MedicineBronx, NY | 2024 Peg's Fight for Life Award | $37,500 | 2024 |
| Massachusetts Institute of TechnologyCambridge, MA | The research project is seeking to tackle a long-standing question on whether the heterogeneity of a tumor is impacting its immune response. Although often perceived as one disease, any cancer lesion is comprised of millions of tumor cells. While some tumor cells seem similar to others, they may be very different in their appearance to the immune system. This phenomenon of high intra-tumor heterogeneity is particularly common in lung cancer. Despite us knowing about the heterogeneity, we currently have no mechanistic understanding of its impact on anti-tumor immunity. Understanding this interplay will help find rational and potent combination treatments with cancer immunotherapy, a relatively new treatment modality activating the patient's own immune system to fight cancer. | $37,500 | 2020 |
| University of Texas SouthwesternDallas, TX | The research project is seeking to understand the role of Telomerase that is expressed by most human cancers, particularly small cell lung cancer. We will target an essential survival mechanism of tumor cells to activate protective antitumor immunity and immune memory. We hypothesize that cytosolic DNA resulting from targeting telomerase with 6TdG treatment induces the cGAS/STING pathway, leading to enhanced antigen presentation and cytokine expression from tumors and dendritic cells (DC), causing the expansion and activation of tumor-specific T cells. If successful, our studies will guide the design of clinical trials. Given that NIH considers SCLC a recalcitrant disease, we believe SCLCs can easily be prioritized to be one of the first cancers to test 6TdG as these tumors do not have effective treatments currently. If we can generate strong preclinical evidence with this proposal, 6TdG can rapidly move in this subset in the clinic. | $37,500 | 2020 |
| University of Texas at AustinAustin, TX | 2025 Peg's Fight for Life Award | $37,500 | 2025 |
| Univ of Texas SW MedicalDallas, TX | Katherine Bensen Hope Award | $37,500 | 2022 |
| Emory UniversityAtlanta, GA | Julie Swedberg YOLO Award | $37,500 | 2024 |
| Massachusetts General HospitalBoston, MA | 2022 Peg's Fight for Life Award | $37,500 | 2024 |
| 0.50 |
| $0 |
| Joe Leach | Board member | 0.50 | $0 |
| Peter Leatherman | Board member | 0.50 | $0 |
| Kostantinos Leventakos | Board member | 0.50 | $0 |
| Steve Link | Board member | 0.50 | $0 |
| Andrew Mcpherson | Board member | 0.50 | $0 |
| Jennifer Olson | Board member | 0.50 | $0 |
| Lori Shipman | Board member | 0.50 | $0 |
| Janet Huss | Chair (1/1-4/1) | 2.50 | $0 |
| Randy Hertog | Chair (4/1-12/31) | 2.50 | $0 |
| Manish Patel | Vice Chair | 1.00 | $0 |
| Anna Kate Bush | Secretary | 1.00 | $0 |
| Mike Koroscik | Treasurer | 1.00 | $0 |
| Teri Cannon | Executive Director (6/16-12/31) | 50.00 | $119,492 |
| Nancy Torrison | Executive Director (1/1-6/16) | 35.00 | $110,300 |
| Nang Her | Finance & Operations Director | 40.00 | $90,517 |
Nearest by size, location and giving pattern in the database. Geography weighs heavily. Treat it as a starting list, not a ranking of fit.
Form 990 · FY2024 · period ending Dec 31, 2024IRS bulk XML
Filing id 202501059349302800
Form 990 · FY2023 · period ending Dec 31, 2023IRS bulk XML
Filing id 202431309349302208
Form 990 · FY2022 · period ending Dec 31, 2022
Filing id 202341329349305689
Form 990 · FY2021 · period ending Dec 31, 2021 · amended
Filing id 202221229349301267
Form 990 · FY2020 · period ending Dec 31, 2020
Filing id 202131119349301503
Form 990 · FY2019 · period ending Dec 31, 2019
Filing id 202001419349301465
Form 990 · FY2018 · period ending Dec 31, 2018
Filing id 201921359349314512
IRS filings are the source for every fact on this page. Nothing a model writes is ever a source; it can only point at a row here.